Date | Price Target | Rating | Analyst |
---|---|---|---|
8/22/2024 | $55.00 | Overweight | Wells Fargo |
6/26/2024 | Overweight | Piper Sandler | |
6/24/2024 | Buy | TD Cowen |
Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00
Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight
TD Cowen initiated coverage of Tectonic Therapeutic with a rating of Buy
S-8 POS - Tectonic Therapeutic, Inc. (0001681087) (Filer)
S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
Leerink Partners analyst David Risinger initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Outperform rating and announces Price Target of $49.
13D
SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)
WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024. 2024 Wells Fargo Healthcare Conference:Date:September 4, 2024Time:3:45 PM ETPresenter:Alise Reicin, MD, President, CEO and Director,
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech
TX45 is an Fc-relaxin fusion protein being evaluated in patients with Group 2 Pulmonary Hypertension (PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF), a serious condition estimated to affect over 600,000 people in the U.S. alone, currently with no approved therapiesPlanned initiation of global, 24-week Phase 2 clinical trial to evaluate TX45 administered subcutaneously in subjects with Group 2 PH due to HFpEF (PH-HFpEF) in the third quarter of 2024, with topline trial results expected in 2026Phase 1a topline trial results of TX45 in healthy volunteers are expected to be released this September, with detailed data to be subsequently presented at a scientific meetingPhase 1b
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech